IMUNOFAN - UNIQUE PEPTIDE IMMUNOMODULATOR
The purpose of NPP BIONOX is to conduct research and development aimed at developing its own chemical engineering technology to create new generations of synthetic regulatory peptides with specified qualitative effects and selective effects on the body.
To this end, Bionox exchanges scientific experience and provides comprehensive assistance to domestic and foreign pharmaceutical companies in mastering the latest technologies in medicine and veterinary medicine. Bionox is creating subsidiaries and joint ventures to meet the growing clinical demand for NPP BIONOX products, increasing production volumes and expanding the geography of use, first of all, of those peptide drugs that have no alternative in world medicine.
IMUNOFAN is synthesized on the basis of the natural peptide hormone of the thymus gland - THYMOPOIETIN. The drug contains as an active pharmacological substance a peptide representing a chain of 6 amino acid residues, the composition and sequence of which are protected by RF patent No. 2062096.
Due to the mechanism of action of its prototype, IMUNOFAN is not an immune stimulant, as well as an immunosuppressant. Imunofan has a modulating effect - it returns immunity indicators to the boundaries of reference values. It increases low and reduces the activity of elevated indicators, ensuring the safety of the drug, as well as the effectiveness and balance of the body's immune response.
According to the composition and mechanism of action, there are currently no analogues of IMUNOFAN. Clinical trials and many years of experience in the therapeutic use of the drug confirm that IMUNOFAN is an effective drug for correcting the immune status in various disorders.
IMUNOFAN is an innovative drug with an immunomodulatory effect. Created by scientists from the Central Research Institute of the Ministry of Health, it is a synthetic analogue of thymopoietin, a peptide hormone that regulates the functional state of the immune system.
IMUNOFAN launches a cascade of natural processes in the immune system, helping to bring it into a state of physiological balance - the state when the immune response to foreign agents will be most effective.
To date, the technology of industrial production of 3 dosage forms of the drug has been developed, mastered and used:
IMUNOFAN solution for injection
IMUNOFAN dosed intranasal spray
THE PHARMACOLOGICAL EFFECTS OF THE DRUG ARE BASED PRIMARILY ON ITS ABILITY TO:
- restore the balance of the redox system of the body;
- to significantly influence the change in the state of the immune system, both in case of its weakening and in case of excessive activity, in a peculiar way by regulating its indicators towards the normalization of the state of the immune system;
- in complex use, to significantly increase the effectiveness of basic therapy in a wide range of pathologies, including due to the qualitative originality of the action in relation to multidrug resistance.
INDICATIONS FOR THE USE OF THE DRUG IN COMPLEX THERAPY AND INDEPENDENTLY:
- oncological diseases;
- opportunistic infections (cytomegalovirus and herpetic infections, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis);
- chronic viral hepatitis;
- chronic brucellosis;
- diphtheria, including bacterial carriage;
- toxemia;
- septicotoxemia;
- septic endocarditis;
- purulent-septic complications in surgical patients;
- broncho-obstructive syndrome;
- cholecystopancreatitis;
- rheumatoid arthritis;
- psoriasis.
